Renal Division, Department of Internal Medicine, University Hospital Gent, Belgium.
Laboratory for Histocompatibility and Immunogenetics, HILA Mechelen, Belgium.
Am J Transplant. 2010 Apr;10(4):943-946. doi: 10.1111/j.1600-6143.2010.03028.x. Epub 2010 Feb 25.
Drug-induced immune thrombocytopenia (DITP) can be caused by numerous drugs. When this condition develops, platelet destruction results from binding of antibodies to normal platelets only in the presence of a sensitizing drug. A recently proposed model suggests that these drug-dependent antibodies are derived from a pool of naturally occurring antibodies with weak affinity for specific epitopes on certain platelet membrane glycoproteins. We describe here a case of DITP secondary to cotrimoxazole exposure in the immediate posttransplantation phase in a renal transplant recipient. Apart from heparin-induced thrombocytopenia, DITP posttransplantation has to the best of our knowledge never been described, perhaps because of its immune-mediated origin. Our case demonstrates that DITP can occur posttransplantation, that cotrimoxazole due to its intensive use in the transplanted population is one of the most likely causative agents and that a timely recognition and treatment might have important consequences for both graft and patient.
药物诱导的免疫性血小板减少症(DITP)可由多种药物引起。当这种情况发生时,血小板的破坏是由于抗体与正常血小板结合,只有在致敏药物存在的情况下才会发生。最近提出的一种模型表明,这些药物依赖性抗体来自于一个自然存在的抗体池,这些抗体对某些血小板膜糖蛋白上的特定表位具有较弱的亲和力。我们在这里描述了一例肾移植受者在移植后即刻因接触复方新诺明而发生的 DITP。据我们所知,除肝素诱导的血小板减少症外,移植后 DITP 从未被描述过,这可能是因为其免疫介导的起源。我们的病例表明,DITP 可在移植后发生,由于复方新诺明在移植人群中的广泛使用,它是最有可能的致病因素之一,及时的识别和治疗可能对移植物和患者都有重要的影响。